title: Pharmacoeconomics of gastrointestinal drug utilisation prior and post Helicobacter pylori eradication.
abstract: BACKGROUND
  Eradication of Helicobacter pylori prevents recurrence of peptic ulcer. In pharmacoeconomic analyses it is often presumed that after successful eradication no more gastrointestinal drugs are used. We investigated this presumed positive monetary effect using General Practitioners prescribing data, including information in diagnosis.
  
  
  METHODS
  From the RNG-database we identified patients with a H. pylori eradication in the years 1997-2000. H. pylori eradication was defined as a prescription of two antibiotics and one gastrointestinal drug on the same day. Patients were divided into a group with diagnosed ulcers and a group without diagnosed ulcers. Gastrointestinal drug costs were calculated for 4 months prior to eradication and 9-12 months post eradication. For comparison costs in all periods were expressed per patient per period. For statistical analysis the paired t-test was used.
  
  
  RESULTS
  One hundred and two patients were eligible for evaluation. Of these patients 35 had a diagnosed ulcer and 67 had not. Generally the number of patients on gastrointestinal drugs decreased (61% prior vs. 33% post), however, the drug costs did not change (Euro 33 prior vs. Euro 34 post). Costs for proton pump inhibitors increased post eradication (Euro 14 prior vs. Euro 28 post). The ulcer and nonulcer group showed similar results.
  
  
  CONCLUSIONS
  Helicobacter pylori eradication is thought to be cost effective, however, we did not find a decrease in costs for all gastrointestinal drugs. There may be a great pharmacoeconomical advantage when it is possible to predict which patients are more likely to 'fail' eradication therapy.
authors.affiliation: Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP), Department of Social Pharmacy, Pharmaco-epidemiology and Pharmacotherapy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors.forename: Rogier M
authors.initials: RM
authors.lastname: Klok
authors.forename: Willem Jan
authors.initials: WJ
authors.lastname: van der Veen
authors.forename: Ger Th
authors.initials: GT
authors.lastname: van der Werf
authors.forename: Paul B
authors.initials: PB
authors.lastname: van den Berg
authors.forename: Jacobus R B J
authors.initials: JR
authors.lastname: Brouwers
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004363:Drug Utilization / Q000191:economics*; D004791:Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D005260:Female; D005765:Gastrointestinal Agents / Q000191:economics* / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D014456:Ulcer / Q000175:diagnosis
chemical_list: D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D054328:Proton Pump Inhibitors